Gene, Cell, & RNA Therapy Landscape Report

Q2: Three new therapies approved

In Q2 2025:

• FDA approved Zevaskyn for recessive dystrophic epidermolysis bullosa (RDEB) and mNexspike for COVID-19

• In China, the country’s first gene therapy for hemophilia B was approved

• Sixty-four percent of the 80 gene therapy trials initiated were for oncology indications, the highest proportion of the past year